AVITA's Q4 sales missed guidance due to hospitals deferring year end purchases. However, January's rebound suggests a strong Q1 is coming. Management's communication misstep on the firm's ...
Throughout the last three months, 5 analysts have evaluated AVITA Medical (NASDAQ:RCEL), offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview ...
Shares of Avita Medical Inc. (RCEL) have gained 20.5% over the past four weeks to close the last trading session at $10.22, but there could still be a solid upside left in the stock if short-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback